Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Public ClinicalTrials.gov record NCT00606502. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC) patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
Study identification
- NCT ID
- NCT00606502
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 201 participants
Conditions and interventions
Conditions
Interventions
- Pralatrexate Drug
- Erlotinib Drug
- Vitamin B12 Dietary Supplement
- Folic Acid Dietary Supplement
Drug · Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Jun 23, 2010
- Completion
- Jun 23, 2010
- Last update posted
- Mar 4, 2021
2008 – 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Donald Berdeaux | Great Falls | Montana | 59405 | — |
| Summit Medical Group | Berkeley Heights | New Jersey | 07922 | — |
| Hematology and Oncology Associates South Jersey | Mount Holly | New Jersey | 08060 | — |
| New York Oncology Hematology-Oncology Associates, P.C. | Latham | New York | 12110 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | — |
| New Bern Cancer Care | New Bern | North Carolina | 28562 | — |
| Signal Point Clinical Research Center | Middletown | Ohio | 45042 | — |
| Baptist Regional Cancer Center | Knoxville | Tennessee | 37920 | — |
| Cancer Therapy and Research Center | San Antonio | Texas | 78229 | — |
| Providence Everett Medical Center | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00606502, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2021 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00606502 live on ClinicalTrials.gov.